Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Membranous nephropathy (MN) represents the leading cause of nephrotic syndrome in adults, which is traditionally categorized as primary and secondary MN. Recent discoveries of novel antigens in MN have generated growing evidence on their prevalence, clinicopathological characteristics and regional diversity. Elucidating the significance of these newly recognized antigens is essential for refining diagnostic accuracy and developing targeted therapeutic strategies. The present study aimed to analyze the antigenic subtypes of MN in central India and to explore their clinicopathological correlations.
A prospective study was conducted at a Tertiary Care Hospital in Central India. All native renal biopsies with diagnosis of MN in a period between January 2023 to August 2025 were included in the study. Immunohistochemistry (IHC) was performed for PLA2R (Sigma Aldrich 1: 200 dilution) in all cases of MN. In PLA2R-negative cases, and all cases of secondary MN with associated disease, additional IHC with thrombospondin type 1 domain-containing 7A (THSD7A) (Thermofisher Scientific 1:500 dilution), neural epidermal growth factor-like 1 (NELL-1) (Thermofisher Scientific 1:200 dilution), Exostosin 1 (EXT1) and Exostosin 2 (EXT2) (Thermofisher Scientific 1:500 dilution) were performed. All IHC were performed on VENTANA Benchmark ULTRA automated immunostainer. Clinicopathological profile of all patients were recorded as per case record form. Statistical analysis was performed using SPSS software.
A total of 60 cases of MN were enrolled during the study period comprising 29 males and 31 females (M:F=1:1.06). The age of patients ranged from 6 to 70 years with 52 adults and 8 children. Adequate tissue was available in 57 cases. PLA2R-associated MN accounted for 75.43% (43 of 57) of biopsy-proven MN cohort. There were 31 cases of MN without associated disease (primary MN), of which 29/31 were positive for PLA2R (93.5%), and remaining 2/30 were negative for PLA2R, THSD7A, NELL-1, EXT1/2. There were 29 cases of MN with associated disease (secondary MN). In this group, IHC positivity rates were PLA2R (51.8%), THSD7A (0%), NELL-1 (3.4%), EXT1/2 (27.5%). Primary MN had significantly higher UPUCR (p=0.02) and lower serum albumin (p=0.04) compared to secondary MN. Serum creatinine was significantly higher (p<0.001) and GFR was lower (p=0.14) in secondary MN as compared to primary MN. Secondary MN affected younger age group as compared to primary MN (p= 0.037) and had significantly lower C3 values (p= 0.007). There were 20 cases of SLE/MCTD. EXT1/2 was positive in 47% (8/17) and PLA2R in 35.3 % (6/17) cases of MN associated with autoimmune disease. EXT1/2 positive MLN was associated with higher proteinuria and presented in younger age compared to EXT1/2 negative cases. However statistical significance was not observed between two groups. Two cases of MLN showed dual positivity for EXT1/2 and PLA2R. 7/8 (87.5%) of pediatric MN were secondary MN.
The present study explores novel antigenic subtypes and clinicopathological profile of MN in central Indian population. We advocate routine application of multiple target antigen staining to enhance diagnostic precision and understanding of the disease. The study endorses refined terminology that links target antigen and disease to improve MN classification and clinical decisions.
